Persea

Develops an allogeneic suicide gene therapy (MTI) to treat liver cancer. The therapy uses allogeneic mesenchymal stem cells transfected with a cyclophosphamide-activated suicide gene (CPA), enhancing tumour sensitivity to chemotherapy. The mechanism enables tumour destruction while generating an immune response that prevents tumour recurrence. Proof of concept carried out in vitro and in vivo.